Welcome to our dedicated page for Salarius Pharmaceuticals news (Ticker: SLRX), a resource for investors and traders seeking the latest updates and insights on Salarius Pharmaceuticals stock.
The news feed for Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX) captures the company’s transition as it integrates Decoy Therapeutics and pivots toward a peptide-conjugate antiviral and oncology platform. Press releases and regulatory announcements describe how Salarius, historically a clinical-stage biopharmaceutical company with oncology assets, completed a strategic merger with Decoy and is preparing to operate under the Decoy Therapeutics name and the Nasdaq ticker symbol DCOY.
Readers following SLRX news can expect updates on corporate transformation, including the planned and then confirmed changes to the corporate name and trading symbol, as well as details of the merger structure, preferred stock issuance and leadership changes documented in company communications and SEC filings. The news flow also highlights capital markets activity, such as underwritten public offerings of common stock and warrants, at-the-market issuances and efforts to regain and maintain compliance with Nasdaq listing standards, including reverse stock splits and panel monitoring.
Sector-specific coverage focuses on drug development and platform progress. Company announcements describe the IMP3ACT peptide-conjugate platform, pan‑coronavirus and broad-acting antiviral programs, and a peptide drug conjugate targeting GI cancers. News items also cover collaborations, notably with Texas Biomedical Research Institute for in vitro testing of peptide conjugate fusion inhibitors across influenza strains including H5N1 avian flu, and recognition from programs such as the Massachusetts Life Sciences Seed Fund, the Google AI startup program, the NVIDIA Inception program and BARDA’s BLUE KNIGHT initiative.
By monitoring this page, investors and observers can review historical and ongoing disclosures around SLRX’s oncology heritage, its integration with Decoy’s AI- and ML-enabled peptide-conjugate platform, financing transactions and interactions with the Nasdaq Capital Market, all drawn from company-issued news and related filings.
Salarius Pharmaceuticals (NASDAQ: SLRX) announced a 1-for-25 reverse stock split effective at 5:00 p.m. ET on October 14, 2022. Trading on a split-adjusted basis will start on October 17, 2022. This measure aims to regain compliance with the $1.00 minimum closing bid price for continued Nasdaq listing. Stockholder approval was granted in June 2022, leading to this decision. The number of shares will decrease from approximately 56.2 million to 2.2 million. Cash will be provided for any fractional shares.
HOUSTON, Sept. 20, 2022 – Salarius Pharmaceuticals (NASDAQ: SLRX) announced its participation in the 2022 Ladenburg Thalmann Healthcare Conference on September 29 in New York City. CEO David Arthur will deliver a corporate presentation and engage in a fireside chat at 10:30 a.m. Eastern Time. The event will be available via live webcast. Salarius develops innovative treatments for cancer, including its lead candidate, seclidemstat, currently in clinical trials for Ewing sarcoma. The company has received various FDA designations for this treatment.
Salarius Pharmaceuticals (NASDAQ: SLRX) recently provided an update on its developmental progress and future plans. The company’s lead candidate, seclidemstat, is advancing in a Phase 1/2 clinical trial for Ewing and related sarcomas, with interim data expected by year-end. Noteworthy is the expansion to 17 clinical sites, including prestigious institutions. Furthermore, the newly acquired SP-3164 is being developed as a targeted protein degrader. Salarius maintains strong financials with $22.6 million in cash, ensuring well-funded operations into 2023.
Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX) has announced the expansion of its Phase 1/2 clinical trial for seclidemstat, a novel treatment for Ewing’s sarcoma and FET-rearranged sarcomas, to include two Mayo Clinic locations in Minnesota and Florida. This trial aims to explore seclidemstat's efficacy and safety in treating pediatric bone cancer and other related sarcomas. Interim data is expected in the second half of 2022, with hopes that seclidemstat will positively impact patient outcomes.
Salarius Pharmaceuticals (NASDAQ: SLRX) has expanded its ongoing Phase 1/2 clinical trial of seclidemstat for Ewing’s sarcoma and related sarcomas to 15 U.S. trial sites, including the prestigious Seattle Cancer Care Alliance and Oregon Health & Sciences University. The trial explores seclidemstat, a targeted LSD1 inhibitor, in various combinations and as a single agent. Interim data is expected in the second half of 2022. Salarius aims to improve prospects for patients with limited treatment options, with seclidemstat already receiving FDA designations for its potential.
Salarius Pharmaceuticals (NASDAQ: SLRX) has announced a collaboration with VolitionRx Limited to enhance the development of its cancer treatment, seclidemstat, utilizing Volition's Nu.Q® technology for rapid epigenetic profiling. Seclidemstat is currently in Phase 1/2 clinical trials targeting various cancers. This partnership aims to derive valuable biomarker data to assess drug activity and engagement noninvasively. Salarius is advancing its programs, including support from the National Pediatric Cancer Foundation and the Cancer Prevention and Research Institute of Texas.
Salarius Pharmaceuticals (Nasdaq: SLRX) will release its Q2 2022 financial results on August 5, 2022, followed by a conference call on August 8, 2022, at 11:00 a.m. ET. The call will discuss financial results for the quarter ending June 30, 2022, alongside recent business updates and upcoming milestones. Salarius is focused on developing cancer therapies like seclidemstat for pediatric cancers and sarcomas. The company has received key designations from the FDA and has ongoing clinical trials, bolstered by support from the National Pediatric Cancer Foundation and CPRIT.
Salarius Pharmaceuticals (NASDAQ:SLRX) announced its participation in the 2022 BIO International Convention in San Diego from June 13-16. The company will update on two drug candidates: SP-3164, a next-generation protein degrader targeting cancer-causing proteins, and seclidemstat, its lead candidate in a Phase 1/2 trial for relapsed Ewing sarcoma. Expected clinical readouts for seclidemstat will occur in the latter half of 2022. CEO David Arthur emphasized the potential of their pipeline to address underserved cancers, reinforcing the importance of the convention for business development opportunities.
Salarius Pharmaceuticals (Nasdaq: SLRX) announced that CEO David Arthur will present at the H.C. Wainwright Global Investment Conference from May 23-26, 2022. The presentation, available on-demand starting May 24, will highlight the company's recent achievements and upcoming milestones related to its leading products, seclidemstat and SP-3164. The presentation can be accessed via a dedicated link and will be available for replay for 90 days. Salarius is focused on developing therapies for sarcomas and pediatric cancers, with seclidemstat currently in clinical trials for Ewing sarcoma.
Salarius Pharmaceuticals (SLRX) reports significant advancements in its drug development programs, notably with SP-3164 and seclidemstat. The FDA pre-IND meeting for SP-3164 has been successfully completed, setting the stage for further studies. Financially, Salarius had $24.2 million in cash as of March 31, 2022, but reported a net loss of $6.1 million for Q1 2022, up from $1.9 million in Q1 2021, primarily due to increased R&D expenses. The annual stockholders meeting is scheduled for June 15, 2022, inviting participation in key proposals.